Older Patients With T2D May Not Benefit From A1C Below 9 Percent.
A study published in JAMA Internal Medicine concluded that for patients with T2DM on metformin and an HbA1c below 9% further efforts to reduce glucose may be more bothersome than beneficial, and therefore glycemic control should move away from a treat-to-target to an individualized strategy. Because additional benefits of further reducing glucose may bring benefits 15 to 20 years later, for older patients, the benefits may be outweighed by burdens of lifelong treatment. The study found that further reducing glucose to 7 percent produced no significant reductions in vision loss, end-stage renal disease, or amputation after 10 years.
Lack Of Exercise, Rather Than Overeating, May Be Fueling America’s Obesity.
Research published in the American Journal of Medicine suggests that under-exercising, rather than overeating, may be at the heart of America’s obesity epidemic, with the data indicating a strong correlation between the rise in obesity and a striking drop in the amount of time Americans spend exercising when not at work over the last 22 years.
The investigators analyzed U.S. NHANES data over the last 20 years, and found the number of women doing no physical activity went from 19.1% in 1994 to 51.7% in 2010, while, and for men from 11.4% in 1994 to 43.5% in 2010.
Letrozole May Help Women With PCOD Become Pregnant.
Research published in NEJM on 750 women, compared clomiphene with letrozole. Approximately 28% of women randomly assigned to take letrozole had a live birth, compared with 19% of those assigned to take clomiphene. Women receiving letrozole also had higher ovulation rates and fewer twin pregnancies. Birth defects for women on both medications were rare.
Hyponatremia May Increase Risk Of Osteoporosis, Fragility Fractures.
A research presented at the ICE and Endocrine Society meeting indicates that hyponatremia quadruples the risk of osteoporosis and fragility fractures raising the hypothesis that hyponatremia is a significant and clinically important risk factor for both osteoporosis and bone fractures in inpatients and outpatients.
FDA Calls For Advisory Panel Meeting Over Risks Tied To Testosterone Products.
An advisory committee meeting of the FDA is set to hold a meeting on Sept. 17 to discuss the risks related to testosterone replacement therapy. The move comes in the wake of FDA’s order in June that all testosterone products carry a general warning about the risk of blood clots in veins.
Single Injection Of FGF1 Protein Reverses Diabetes Symptoms In Mice.
A study in Nature found that when mice with the human equivalent of T2DM were injected with the protein FGF1, their blood sugar levels returned to normal over two days. Just one injection both regulated these levels and even helped reverse insulin insensitivity. The injection did not cause the kinds of side effects commonly seen with many diabetes medications. The mechanism of FGF-1 still isn’t fully understood, but the protein’s ability to stimulate growth seems to be independent of its effect on glucose.
Sensor That Uses Saliva To Measure Sugar Levels Being Developed.
A new type of sensor for people with diabetes is being developed to measure sugar levels in the body using saliva instead of blood. Researchers have successfully tested it using artificial saliva. The sensor uses light, metal and a special enzyme that changes color when exposed to blood sugar. The research is published in Nanophotonics.
miR-34a Target For New Therapies In Osteoporosis, Bone metastases.
A letter in Nature suggests microRNA molecule miR-34a is a key suppressor of osteoclast development, bone resorption, and the bone metastatic niche, and it could be a target for new therapies in osteoporosis and cancers that metastasize to bone. Researchers examined several microRNAs related to cancers during a time course of bone marrow osteoclastogenesis assay and determined that miR-34a blocked the development of osteoclasts, while the related microRNAs miR-34b and miR-34c did not. MiR-34a was rapidly downregulated byRANKL and further diminished by rosiglitazone, while levels of miR-34b/c were unaffected and expressed at much lower levels than miR-34a.
Shift Work Linked To Increased Risk Of Type 2 Diabetes.
A research in Occupational and Environmental Medicine suggests that shift work may be associated with a higher risk of developing type 2 diabetes after analyzing data from 12 international studies involving more than 226,500 people. While the findings weren’t able to show a direct cause-and-effect relationship, they showed any amount of shift work linked to a 9 percent greater risk for developing diabetes. In men the risk jumped to 37 percent. Possible explanations include disrupting sleeping and eating patterns.
Once-Weekly Dulaglutide Noninferior To Once-Daily Liraglutide.
A research in The Lancet indicates that the investigational once-weekly dulaglutide (Eli Lilly) is noninferior to once-daily liraglutide, providing similar HbA1c reductions, in adults with T2DM poorly controlled with metformin. Meanwhile, the GLP-1 agonists showed similar tolerability.